13 C NMR (100 MHz, CD 3 OD): δ174. 9, 174.5, 157.3, 143.9, 143.7, 141.2, 127.3, 126.7, 124.9, 124.8, 119.5, 66.6, 53.8, 38.6, 35.8, 31.6, 30.9, 29.4, 29.3, 29.2, 29.0, 28.9, 28.5, 25.7, 22.9, 22.3, 
LCMS (ESI) calcd. for C35H51N2O5 ([M+H]
+ ) 579.4, obsd. 579.3.
To a solution of Fmoc-Lys(myristoyl)-OH (2) (3.0 g, 5.18 mmol) in THF (100 ml) was added Lawesson's reagent (1.9 g, 4.66 mmol) and the resulting mixture was stirred at room temperature overnight. After removing THF using a rotary evaporator, the residue was purified using silica gel column chromatography with 50:1 CH 2 Cl 2 :CH 3 OH to give compound 3 as a white solid (2.0 g, 64.8% yield). 
S3
141. 1, 127.4, 126.8, 124.9, 124.8, 119.6, 119.5, 66.6, 53.8, 45.7, 45.2, 31.7, 31.0, 29.4, 29.3, 29.1, 28.6, 26.8, 23.0, 22.4, 13.1. LCMS (ESI) calcd. for C35H51N2O4S [M+H] + 595.4, obsd. 595.4.
Solid-phase synthesis of thiomyristoyl peptides
Thiomyristoyl peptide was synthesized using standard Fmoc/tBu chemistry O-benzotriazol-N,N,N',N'-tetramethyluronium hexafluorophosphate/1-hydroxybenzotriazol (HBTU/HOBt) protocol. BHJH-TM1, BHJH-TM2, BHJH-TM3 and BH-TM4 were synthesized with Wang resin. JH-TM5 was synthesized with Rink resin.
Modified lysine was incorporated using L-Fmoc-Lys(thiomyrsitoyl)-OH (3) . Cleavage from the resin and removal of all protecting groups were done by incubating the resin with trifluoroacetic acid (TFA) containing phenol (5%), thioanisole (5%), ethanedithiol (2.5%), and water (5%) for 2 h. 
Cloning, expression and purification of human Sirtuins
Human Sirt6, Sirt1and Sirt3 were expressed as previously described 2, followed by Ni-affinity column purification to remove any undigested SirT2. The tag-free Sirt2 was further purified on a Superdex 75 column (Biorad). The protein was eluted with 20mM Tris-HCl, pH 8.0, 500mM NaCl.
After concentration, the target protein was frozen at -80℃.
Inhibition assay for Sirt6
Sirt6 demyristoylation. When using the myristoyl H3K9 peptide as the substrate, different concentrations 90 L of 200 mM HCl and 320 mM acetic acid in methanol. After centrifugation to remove precipitated proteins, the supernatant was analyzed by HPLC on a reverse phase C18 column (250 × 4.6 mm, 90 A, 10 m, GraceVydac, Southborough, MA) with a linear gradient of 0% to 20% B for 10 min (0.5 mL/min). Product quantification was based on the area of absorption monitored at 280 nm; assuming hydrolysis of the acyl group does not affect the absorption. All reactions were duplicated.
Inhibition Assay for Sirt1, Sirt2, and Sirt3.
The assay conditions were similar to that described above for Sirt6 with the following differences:
KQTAR(AcK)STGGWW was used as the substrate, reaction time was 5 min (Sirt1 and Sirt2) or 10 min (Sirt3).
Sirt6 inhibition assay in mammalian cells.
HEK293T cells were cultured in DMEM medium containing 10% heat-inactivated fetal bovine serum.
The pCMV-Tag 4A vector containing TNFα gene was transfected into cells using FuGene 6 transfection reagent. µM) were incubated with cells for 6 h, followed by incubation of Alk14 (50 µM) and bredeldin A (4 µg/mL) for another 6 h. Cells were collected and lysed using lysis buffer (25 mM Tris pH 7.4, 150 mM NaCl, 10% glycerol and 1 % Nonidet P-40) containing protease inhibitor cocktail (1:200 dilution). After centrifugation at 14,000 g for 10 min, the supernatant was collected for immunoprecipitation. 500 µg of total proteins were used and incubated with 20 µL suspension of anti-Flag M2 affinity gel at 4 ˚C for 2 h. The affinity gel was then washed three times with immunoprecipitation washing buffer (25 mM Tris pH 7.4, 150 mM NaCl, 0.2% Nonidet P-40).
The gel was re-suspended in 18 µL of immunoprecipitation washing buffer. Figure S12. Inhibition curves of BH-TM4, ARK(TMy)ST, and AGK2 on the deacetylase activity of Sirt6., BH-TM4 concentrations used in this assay were 0, 1, 2.5, 5, 10, 20 and 40 μM. ARK(TAc)ST concentrations used were 0, 1.56, 3.13, 6.25, 12.5, 25, 50 and 100 μM. AGK2 concentrations used were 0, 9.4, 18.8, 37.5, 75, 150 and 300 μM. The experiments were performed in duplicate. 
